SEC Form 4 · accession 0000899243-17-002120
Seres Therapeutics, Inc. · MCRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roger Pomerantz
Officer — President and CEO · Director
Period of report
Jan 26, 2017
Accepted (ET)
Jan 27, 2017 · 5:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609809
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $9.89 | Jan 26, 2017 | A | 261,000 | A | — | Jan 25, 2027 | Common Stock | 261,000 | 261,000 | D |
Explanation of responses
- F1The option will vest as to 25% of the shares on January 26, 2018. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
Remarks
Exhibit List Exhibit 24 - Power of Attorney